Massachusetts-based CAMP4 Therapeutics Corporation (Nasdaq: CAMP) has received clearance from Australia's Therapeutic Goods Administration (TGA) and local Human Research Ethics Committee to initiate a Phase I/II first-in-human trial of CMP-002 in patients with SYNGAP1-related disorder — a rare neurodevelopmental condition for which no approved disease-modifying therapy exists. The clearance also triggers a second closing under CAMP4's September 2025 Securities Purchase Agreement, making the company eligible to raise up to an additional USD 50 million through a private placement, with investors including Janus Henderson Investors, Balyasny Asset Management, and Vivo Capital.
CMP-002 is an antisense oligonucleotide (ASO) administered intrathecally, designed to bind to a SYNGAP1-specific regulatory RNA (regRNA) and thereby increase transcription from the intact allele, restoring SynGAP protein toward wild-type levels. In preclinical studies, the compound demonstrated dose-dependent protein upregulation in patient-derived neurons, reversal of behavioral phenotypes in a humanized haploinsufficient mouse model, statistically significant improvement in seizure parameters in a chemically induced seizure model, and broad CNS distribution with protein upregulation in non-human primates. Australia was selected as the initial filing jurisdiction based on regional clinical expertise in SYNGAP1 and the TGA's review efficiency; CAMP4 states it is pursuing additional regulatory filings to expand enrollment internationally. Specific patient enrollment numbers and primary endpoints for the Phase I/II trial have not been disclosed.
SYNGAP1-related disorder arises from de novo loss-of-function mutations in SYNGAP1, reducing SynGAP protein to approximately 50% of normal levels. SynGAP is a postsynaptic RasGAP that restrains Ras/MAPK signaling at excitatory synapses; haploinsufficiency produces elevated basal Ras activity, occludes long-term potentiation, and disrupts cortical circuit assembly during a postnatal critical period. The condition affects more than 10,000 individuals in the US, with intellectual disability present in all patients, epilepsy in approximately 85%, and roughly 30% non-verbal. Symptomatic management relies on broadly approved antiseizure medications; none address the underlying protein deficit.
CMP-002's regRNA-targeting mechanism is distinct from the better-characterized NMD-blocking ASO strategy used by zorevunersen (STK-001), Stoke Therapeutics' (Nasdaq: STOK) candidate that upregulates SCN1A in Dravet syndrome by redirecting nonproductive splicing. CAMP4's RAP Platform maps gene-specific regulatory RNAs to achieve transcriptional amplification, a mechanism the company has also applied to CPS1 in urea cycle disorders. The intrathecally delivered ASO modality itself is well precedented in CNS rare disease, with tofersen (Qalsody) for SOD1-ALS establishing regulatory acceptance for this route.